RxDoctor Payments DataLook up a doctor →

Kevin Barber, MD

Ophthalmology · Deland, FLNPI 1184612269

Payments from drug & device makers

$1,152,067in general payments, 2019–2025

Across 1,836 payments — averaging $627.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$850K
  • Glaukos Corporation$280K
  • Alcon$20K
  • Beaver-visitec International, Inc.$700
  • NEW World Medical,inc.$439
  • AbbVie$345
  • plus $200 from 7 others
$4,161in research payments, 2019–2025

Across 1 payment — averaging $4161.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$4K

What the payments were for

  • Consulting fees$47,28384%
  • Speaking & faculty fees$3,7807%
  • Travel & lodging$1,6003%
  • Food & beverage$3,5416%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,152,067 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$190,181
Medicare patients
230
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod14$4,348
Prednisolone Acetate11$306
Latanoprost22$189
Timolol Maleate14$109

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Deland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →